Trial Profile
A Study to Evaluate the Clinical and Imaging Outcomes of Everolimus Eluting Bioresorbable Scaffolds (Absorb) in Patients With Focal Tibial and Distal Popliteal Lesions
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Chronic limb-threatening ischemia; Ischaemia
- Focus Adverse reactions; Therapeutic Use
- 19 May 2016 New trial record